Menu Search
Equities

Veracyte Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
12V:BER

Veracyte Inc

Actions
  • Price (EUR)20.60
  • Today's Change-0.80 / -3.74%
  • Shares traded--
  • 1 Year change-10.43%
  • Beta1.9774
Data delayed at least 15 minutes, as of Jul 18 2025 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

  • Revenue in USD (TTM)463.39m
  • Net income in USD33.05m
  • Incorporated2006
  • Employees824.00
  • Location
    Veracyte Inc6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.